The scarcity of new drugs for neuropsychiatric disorders contrasts with the extraordinary advances in neuroscience research to date. Focusing from bench to bedside, and built with thought-leaders at Sage Therapeutics, Janssen, Lundbeck, and Roche, the 3rd Annual Neuropsychiatric Drug Development Summit will unravel the complexities of developing truly clinically transformative neuropsychiatric drugs. With an emphasis on depressive disorders, schizophrenia, anxiety, and PTSD, this industry-defining meeting will provide the platform for industry and academic thought leaders to exchange scientific advances in our understanding of brain receptors to identify and validate new targets.

Uniting 80+ drug developers from all corners of the world, Neuropsychiatric Drug Development is your opportunity to discuss in-depth, how to push forward the frontiers of neuropsychiatric drug development to develop the next generation of more clinically effective therapeutics.

For more information, please visit: https://npd-summit.com/